Streetwise Biotechnology / Pharmaceuticals Articles


Why Tiny ITUS's CAR-T Therapy Could Be a Big Deal in Cancer Treatment

Contributed Opinion
  ()
With CAR-T being the hottest space in cancer therapy, Daniel Carlson of Tailwinds Research profiles an innovative company that has been collaborating with a major cancer center. read more >

Canadian Biopharma to Outlicense Pain Drug to South Korean Firm

Research Report
  ()
An Echelon Wealth Partners report discussed the deal terms. read more >

Biopharma's Positive FDA Meeting Outlines Path Forward for Trial

Research Report
  ()
A ROTH Capital Partners note explained the outcome of the tÍte-a-tÍte and its implications. read more >

Final Approval of Biopharma's Lead Candidate Both Likely and Imminent

Research Report
  ()
A ROTH Capital Partners report provided the takeaways from a recent meeting with the management team for this company, which is targeting an orphan indication. read more >
News Update

Drug Company Receives $5 Million Milestone Payment

News Update
  ()
Company entitled to receive quarterly earn-out payments from patent agreement. read more >

Oncology-Focused Biotech Receives Orphan Status for AML Drug

Research Report
  ()
An H.C. Wainwright & Co. report provided an update on two of this company's four product candidates. read more >

Investor Opportunity Arises from Biopharma's Share Price Weakness on Competitor News

Research Report
  ()
An analyst discussed the implications to this firm of a competitive product's advancement. read more >
News Update

Neurosciences Company Reports Potential for Improved Safety Profile for Alzheimer's Treatment

News Update
  ()
The substance shows potential for an improved safety profile in direct comparison to other Amyloid Beta-Directed Antibodies in clinical development. read more >

Coverage Initiated on Developer of Brachytherapy Products for Cancer Treatment

Research Report
  ()
H.C. Wainwright & Co. analyst Jason Kolbert provided the rationale for investment in this company. read more >
News Update

As Nitric Oxide Comes Off Patent, Lower-Cost Options for Life Saving Drug Becoming Possible

  ()
Dr. Ronald Day, a pediatric cardiologist at the University of Utah, has been using nitric oxide to treat children with pulmonary hypertension. Now, with a court ruling invalidating much of a drug patent for nitric oxide, lower-cost options might become available. read more >

Biotech Marks Progress on Programs for Cancer, Infectious Diseases

Research Report
  ()
This firm, focused on immuno-oncology and infectious diseases including Ebola and Zika, is moving forward on a variety of fronts, according to a Maxim Group analyst. read more >

Biopharma Signs Multimillion-Dollar Deal for Key Products in China

Research Report
  ()
An H.C. Wainwright & Co. report reviewed the arrangement. read more >
News Update

U.S. Medical Device Firm Pursues ISO 13485 Certification

News Update
  ()
With this move, this company aims for fast-tracked regulatory approval for its nitric oxide delivery system. read more >

Cash Stream from Licensing Deal to Help Biopharma Advance Lead Drug

Research Report
  ()
A Laidlaw & Co. report discussed this firm's revenue and near-term, clinical catalysts. read more >

Biotech Releases White Paper on Alzheimer's Disease Candidate

  ()
A company focused on treatment of neurodegenerative diseases has issued a white paper discussing its lead candidate. read more >

Interim Readout for Pharma Trial 'Delivers Home Run'

Research Report
  ()
An H.C. Wainwright & Co. report discussed the implications of data indicating "overwhelming evidence of efficacy" for this company's nonantibiotic anti-infective for treatment of catheter-related bloodstream infections. read more >

Biopharma Releases New Antibiotic in the US for Complicated UTIs

Research Report
  ()
A LifeSci Capital report reviewed why uptake of a drug that targets complicated urinary tract infections could be significant and swift. read more >

Australian Regenerative Medicine Firm 'Lands a Great Partner in China'

Research Report
  ()
A Maxim Group report reviewed the deal between the two companies. read more >

Cannabis Firm Targets Sexual Health and Wellness

Contributed Opinion
  ()
California, with nearly 40 million residents, offers a cannabis market as large as the whole of Canada, says Ron Struthers, editor of Struthers Resource Stock Report. He believes that companies that have a road into California will gain early traction, and he profiles one such firm. read more >
News Update

Preclinical Data for Alzheimer's Therapy to Be Presented at AAIC

  ()
A poster outlining data from this company's lead candidate, which targets toxic oligomers identified as a potential cause of Alzheimer's disease, will be presented at the Alzheimer's Association International Conference (AAIC). read more >

Study Shows Biopharma's Lead Drug Mediates T Cell Tumor Infiltration

Research Report
  ()
An Echelon Wealth Partners report discussed this firm's stock performance and how a recent clinical trial update impacted it. read more >

Coverage Initiated on 'True Original' Using RNAi to Enhance Cancer Immunotherapy

Research Report
  ()
An H.C. Wainwright & Co. report outlined the thesis for investing in this emerging biotech. read more >

Target Price Increased on Biotech After Q2/18 Revenue Record, Beat

Research Report
  ()
A Maxim Group report explained the likely reasons behind revenue growth for the firm, which produces media used in development of cell therapies. read more >

EpiPen Rival Lands Major Partner

Research Report
  ()
An H.C. Wainwright & Co. report explains the deal, which concerns a new single-dose epinephrine injection for severe allergic reactions. read more >

Coverage Initiated on Biopharma with 'Opioid Sparing Solution for Post-Op Pain'

Research Report
  ()
An H.C. Wainwright & Co. report highlighted the advantages, status and potential of this lead asset. read more >
Showing Results: 1 to 25 of 56 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"PMN anticipates launching its first in-human trial in 2019 of PMN310."
– John Vandermosten, Zacks Small-Cap Research